Importantly however, in vivo studies with AG-881 and other mutant IDH inhibitors have shown that although treatment inhibits tumor growth, reduces cell density 57, and may extend patient survival, there is no evidence of clearly detectable tumor shrinkage [9 and http://investor.agios.com/]. Here, IDH2 is linked to neoplasm.